Vaccination and HIV: A review of the literature

Vaccine

Volumn 18, Issue 9-10, 1999, Pages 825-831

  Rousseau, M C ^a   Moreau, J ^a   Delmont, J ^a  

^a Department of Infectious Diseases   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CHICKENPOX VACCINE; CHOLERA VACCINE; DIPHTHERIA VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INACTIVATED VACCINE; LIVE VACCINE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; MUMPS VACCINE; PNEUMOCOCCUS VACCINE; TYPHOID VACCINE; VACCINE; YELLOW FEVER VACCINE;

HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOSTIMULATION; IMMUNOTOXICITY; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRUS LOAD;

EID: 0032722361     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00321-7     Document Type: Article

References (66)

1. Vilmer E. Communication orale aux journées CISIH-Bichat Claude Bernard le 22/05/96 à Paris sur le thème vaccinations chez les sujets infectés par le VIH.
2. Bouchaud O. Vaccination chez les sujets infectés par le VIH. La lettre de l'infectiologue. 11:1996;564-565.
3. Stanley S., Ostrowski M., Justement J.S., et al. Effects on immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1? N. Engl. J. Med. 334:1996;1222-1230.
4. Nurmi T., Koskela P. Immunosuppressive effect of pneumococcal vaccine contaminated with blood-group-A-like substance. Lancet. i:1988;771.
5. Ruder H., Kerling F., Daniel V., Korn K., Wassmuth R. Decreased alloreactivity after vaccination against hepatitis B. Transplantation. 59:1995;1339-1342.
6. Karp C.L., Wysocka, Wahl L.M., et al. Mechanism of suppression of cell-mediated immunity by measles virus. Science. 273:1996;228-231.
7. Francioli P. Immunodéficience et voyages. Med. Hyg. 49:1991;2326-2334.
8. Porter J.D. Mycobacteriosis and HIV infections: the new public health challenge. J. Antimicrob. Chemother. 37:1996;113-120.
9. Small P.M., et al. N. Engl. J. Med. 328:1993;1137-1144.
10. Talbot E.A., Perkins M.D., Fagunes S., et al. Disseminated bacille Calmette-Guerin disease after vaccination: case report and review. Clin. Infect. Dis. 24:1997;1139-1146.
11. Courpotin. Oral communication. Colloque sur les Vaccinations chez les sujets infectés par le VIH. 22-05-96. Paris.
12. Wilson M.E., Von Reyn C.F., Fineberg H.V. Infections in HIV-infected travelers: risks and prevention. Ann. Intern. Med. 114:1991;582-592.
13. Conlon C.P. The immunocompromised traveller. Br. Med. Bull. 49:1993;412-422.
14. ACIP, Advisory Commitee on Immunization Practices. US Department of Health and Human Services-Center for Disease Control MMWR, 1989, (38)5:64-76.
15. International travel and health vaccination requirements and health advice. 1997;122 World Health Organization, Geneva.
16. Recommendations on immunizations and the use of immunoglobulins of immunocompromised infants, children and adults. MMWR. 42:1993;1-18.
17. Extended vaccination programme. 1995;World Health Organization Geneva.
18. Hill D.R., Pearson R.D. Measles prophylaxis for international travel. Ann. Int. Med. 111:1989;699-701.
19. Wallace M.R., Hooper D.G., Graves S.J., et al. Measles seroprevalence and vaccine response in HIV-infected adults. Vaccine. 12:1994;1222-1224.
20. Von Reyn C.F., Clements C.J., Mann J.M. Human immunodeficiency virus infection and routine childhood immunization. Lancet. 2:1987;669-672.
21. Arpadi S.M., Markowitz L.E., Baughman A.L., et al. Measles antibody in vaccinated human immunodeficiency virus type-1 infected children. Pediatrics. 97:1996;653-657.
22. Oshitani H., Suzuki H., Mpabalwani M.E., et al. Measles case fatality by sex, vaccination status, and HIV-1 antibody in Zambian children. Lancet. 348:1996;415.
23. Krasinski K., Borkowsky W. Measles and measles immunity in children infected with human immunodeficiency virus. JAMA. 261:1989;2512-2516.
24. Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection, 1993. MMWR, 1996;45:603-6.
25. Rudy B.J., Rustein R.M., Pinto-Marin J. Response to measles immunization in children infected with human immunodeficiency virus. J. Pediatr. 125:1994;72-74.
26. Larussa P., Steinberg S., Gershon A. Varicella vaccine for immunocompromised children: results of collaborative studies in the United States and Canada. J. Infect. Dis. 174:1996;S320-S323.
27. Gershon A., Mervish N., Larussa P., et al. Varicella-zoster virus infection in children with underlying human immunodeficiency virus infection. J. Infect. Dis. 176:1997;496-500.
28. Vilde J.L. Vaccinations chez l'adulte. Dormont J. Prise en charge des personnes atteintes par le sida. 1996;74-79 Flammarion ed Paris.
29. Weiss P.J., Wallace M.R., Oldfeld E.C., et al. Response of recent human immunodeficiency virus seroconverters to the pneumococcal polysaccharide vaccine and Haemophilus influenzae type b conjugate vaccine. J. Infect. Dis. 171:1995;1217-1222.
30. King J., Vink P., Farley J., et al. Safety and immunogenicity of three doses of a five-valent pneumococcal conjugate vaccine in children younger than two years with and without human immunodeficiency virus infection. Pediatrics. 99:1997;575-580.
31. Rodriguez-Barredas M.C., Musher D.M., Lahart C., et al. Antibodies to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine. J. Infect. Dis. 165:1992;553-556.
32. Huang K., Ruber F., Rinaldo C., et al. Antibody response after influenza and pneumococcal immunization in HIV-infected men. JAMA. 257:1987;2047-2050.
33. Kroon F.P., Van Dissel I.T., de Jong J.C., et al. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS. 8:1994;469-476.
34. Rodriguez-Barredas M.C., Groover J.E., Lacke C.E., et al. IgG antibody to pneumococcal capsular polysaccharide in human immunodeficiency virus infected subjects: persistence of antibody in responders, revaccination in nonresponders, and relationship of immunoglobulin allotype to response. J. Infect. Dis. 173:1996;1347-1353.
35. Arpadi S., Back S., o'Brien J., et al. Antibodies to pneumococcal capsular polysaccharides in children with human immunodeficiency virus infection given polyvalent pneumococcal vaccine. J. Pediatr. 125:1994;77-79.
36. Pneumococcal polysaccharide vaccine. MMWR. 38:1989;64-76.
37. Fedson D., Henrichsen J., Makelä P.H., et al. WHO recommendations on pneumococcal vaccination: immunization of elderly people with polyvalent pneumococcal vaccine. Infection. 6:1989;91-95.
38. Quotidien du Medecin, 1998;6236:9.
39. Brichacek B., Swindells S., Janoff E.N., et al. Increased plasma human immunodeficiency virus type-1 burden following antigenic challenge with pneumococcal vaccine. J. Infect. Dis. 174:1996;1191-1199.
40. Intravenous Immunoglobulin Study Group. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic HIV infection. N. Engl. J. Med. 325:1991;73-80.
41. Schlamm H.T., Yancovitz S.R. Haemophilus influenzae pneumonia in young adults with AIDS, ARC, or risk of AIDS. Am. J. Med. 86:1989;11-14.
42. Steinhoff D.V., Johnson C.L., Philipps P., et al. Safety and immunogenicity of Haemophilus influenzae type b vaccines in men with human immunideficiency virus infection. N. Engl. J. Med. 325:1991;1837-1842.
43. Kroon F.P., van Dissel J.T., Rijkers G.T., et al. Antibody response to Haemophilus influenzae type b vaccine in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus. Clin. Infect. Dis. 25:1997;600-606.
44. Peters V., Sood S.K. Immunity to Haemophilus influenzae type b polysaccharide capsule in children with human immunodeficiency virus infection immunized with a single dose of haemophilus vaccine. J. Pediatr. 125:1994;74-77.
45. Fowke K., D'Amico D., Chernoff D., et al. Immunologic and virologic evaluation after influenza vaccination of HIV-1 infected patients. AIDS. 11:1997;1013-1021.
46. Donovan R., Moore E., Bush C.E., et al. Changes in plasma HIV RNA levels and CD4 cell counts after vaccination of pediatric patients. AIDS. 11:1997;1054-1056.
47. Da Martino M., Podda A., Sinangil F., et al. Acellular pertussis vaccine in children with perinatal human immunodeficiency virus type-1 infection. Vaccine. 15:1997;1235-1238.
48. Hadler S.C. Hepatitis B prevention and human immunodeficiency virus (HIV) infection. Ann. Int. Med. 109:1988;92-93.
49. Zuccotti G.V., Rival E., Flumine P., et al. Hepatitis B vaccination in infants of mothers infected with human immunodeficiency virus. J. Pediatr. 125:1994;70-72.
50. Scolfaro C., Fiammengo P., Balbo L., et al. Hepatitis B vaccination in HIV-1-infected children: double efficacy doubling the paediatric dose. AIDS. 10:1996;1169-1170.
51. Wong E.K., Bodsworth N.J., Slade M.A., et al. Response to hepatitis B vaccination in a primary care setting: influence of HIV infection, CD4+ lymphocyte count and vaccination schedule. Int. J. STD AIDS. 7:1996;490-494.
52. Hibberd P.L., Rubin R.H. Approach to immunization in the immunosuppressed host. Infect Dis. Clin. North Am. 4:1990;123-142.
53. Cheeseman S.H., Davaro R.E., Ellison R.T. Hepatitis B vaccination and plasma HIV-1 RNA. N. Engl. J. Med. 334:1996;1272.
54. Glesby M.J., Hoover D.R., Farzadegan H., et al. The effect of influenza vaccination on human immunodeficiency virus type-1 load: a randomised, double-blind, placebo-controlled study. J. Infect. Dis. 174:1996;1332-1336.
55. Jackson C.R., Vavro C.L., Valentine M.E., et al. Effects of influenza immunization and virologic characteristics of pediatric patients infected with human immunodeficiency virus. Pediatr. Infect. Dis. 16:1997;200-204.
56. + individuals. Clin. Exp. Immunol. 104:1996;203-207.
57. Prevention and control of influenzae recommandations of the immunization practices advisory committee (ACIP). MMWR, 1995;44:14-8.
58. Delmont J., Igo-Kemenes A., Peyron F., et al. Voyage du sujet immunodéficient. Med. Trop. 57:1997;452-456.
59. Freestone D.S. Yellow fever vacine. Plotkin S.A., Mortimer E.A. Vaccines. 1988;387-419 WB Saunders Co, Philadelphia.
60. Goujon C, Feuillie V, Touir M et al. Good tolerance and efficacy of yellow fever vaccine among carries of human immunodeficiency virus. Oral communication to CMTI 4, Acapulco, Mexique, 27-29-04-1995.
61. Bodsworth N., Neilsen G., Donovan B. The effect of immunization with inactivated hepatitis A vaccine on the clinical course of HIV-1 infection: 1 year follow-up. AIDS. 11:1997;747-749.
62. Koch S., Steffen R. Meningococcal disease in travelers: vaccination recommendations. J. Travel Med. 1:1994;4-7.
63. Neilsen G.A., Bodsworth N.J., Watts N. Response to hepatitis A vaccination in human immunodeficiency virus-infected and uninfected homosexual men. J. Infect. Dis. 176:1997;1064-1067.
64. Denning D, Kaneko Y. Should travelers to Asia be vaccinated against Japanese encephalitis? Lancet 1987;853-854.
65. Adle-Biassette H., Bourhy H., Gisselbrecht M., et al. Rabies encephalitis in a patient with AIDS: a clinicopathological study. Acta Neuropathol. 92:1996;415-420.
66. Glaser J.B., Volpe S., Aguirre A., et al. Zidovuline improves response to pneumococcal vaccine among persons with AIDS and AIDS-related complex. J. Infect. Dis. 164:1991;761-764.